Cai Ming, Chen Xuan, Shan Jieling, Yang Ruoyu, Guo Qi, Bi Xia, Xu Ping, Shi Xiangrong, Chu Lixi, Wang Liyan
Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
School of Kinesiology, Shanghai University of Sport, Shanghai, China.
Front Pharmacol. 2021 Apr 30;12:643619. doi: 10.3389/fphar.2021.643619. eCollection 2021.
COVID-19 is a highly infectious respiratory virus, which can proliferate by invading the ACE2 receptor of host cells. Clinical studies have found that the virus can cause dyspnea, pneumonia and other cardiopulmonary system damage. In severe cases, it can lead to respiratory failure and even death. Although there are currently no effective drugs or vaccines for the prevention and treatment of COVID-19, the patient's prognosis recovery can be effectively improved by ameliorating the dysfunction of the respiratory system, cardiovascular systems, and immune function. Intermittent hypoxic preconditioning (IHP) as a new non-drug treatment has been applied in the clinical and rehabilitative practice for treating chronic obstructive pulmonary disease (COPD), diabetes, coronary heart disease, heart failure, hypertension, and other diseases. Many clinical studies have confirmed that IHP can improve the cardiopulmonary function of patients and increase the cardiorespiratory fitness and the tolerance of tissues and organs to ischemia. This article introduces the physiological and biochemical functions of IHP and proposes the potential application plan of IHP for the rehabilitation of patients with COVID-19, so as to provide a better prognosis for patients and speed up the recovery of the disease. The aim of this narrative review is to propose possible causes and pathophysiology of COVID-19 based on the mechanisms of the oxidative stress, inflammation, and immune response, and to provide a new, safe and efficacious strategy for the better rehabilitation from COVID-19.
新型冠状病毒肺炎（COVID-19）是一种高传染性的呼吸道病毒，可通过侵入宿主细胞的血管紧张素转换酶2（ACE2）受体进行增殖。临床研究发现，该病毒可导致呼吸困难、肺炎等心肺系统损伤。严重时，可导致呼吸衰竭甚至死亡。虽然目前尚无预防和治疗COVID-19的有效药物或疫苗，但通过改善呼吸系统、心血管系统和免疫功能的功能障碍，可有效改善患者的预后恢复情况。间歇性低氧预处理（IHP）作为一种新的非药物治疗方法，已应用于慢性阻塞性肺疾病（COPD）、糖尿病、冠心病、心力衰竭、高血压等疾病的临床和康复治疗中。许多临床研究证实，IHP可改善患者的心肺功能，提高心肺适应性以及组织器官对缺血的耐受性。本文介绍了IHP的生理生化功能，并提出了IHP在COVID-19患者康复中的潜在应用方案，以期为患者提供更好的预后，加速疾病康复。本叙述性综述的目的是基于氧化应激、炎症和免疫反应机制，提出COVID-19可能的病因和病理生理学，并为COVID-19更好的康复提供一种新的、安全有效的策略。
